James Mulshine to Combined Modality Therapy
This is a "connection" page, showing publications James Mulshine has written about Combined Modality Therapy.
Connection Strength
0.125
-
Lung cancer: current therapies and new targeted treatments. Lancet. 2017 01 21; 389(10066):299-311.
Score: 0.032
-
Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. Lung Cancer. 1994 Mar; 10 Suppl 1:S73-81.
Score: 0.027
-
Treatment of non-small-cell lung cancer. J Clin Oncol. 1986 Nov; 4(11):1704-15.
Score: 0.016
-
Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S20-6.
Score: 0.016
-
Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol. 1996 Mar; 14(3):806-13.
Score: 0.008
-
Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl. 1996; 24:173-85.
Score: 0.008
-
Pre-operative and post-operative treatments in stage III NSCLC. Lung Cancer. 1994 Mar; 10 Suppl 1:S15-7.
Score: 0.007
-
Second IASLC Workshop on Combined Radiotherapy and Chemotherapy Modalities in Lung Cancer. Biological basis of combined therapy. Lung Cancer. 1994 Mar; 10 Suppl 1:S3-5.
Score: 0.007
-
Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992 Jun; 53(6):992-8.
Score: 0.006